All In Biotech

Free tool

FAERS Monitor: Qelbree

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211964 or its brand name (Qelbree, Viloxazine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,309

Serious

400

31% of reports

Hospitalization

86

Death reported

10

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache146
  • vomiting132
  • nausea130
  • migraine124
  • fatigue109
  • insomnia109
  • somnolence87
  • drug ineffective82
  • suicidal ideation82
  • withdrawal syndrome57
  • anxiety56
  • product dose omission issue51
  • depression45
  • anger44
  • dizziness44

Reports by year received

View as table
YearReports
20134
20201
202153
2022215
2023204
2024186
2025285
2026361

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,850 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
withdrawal syndromeSignal5721.816.91,113
angerSignal4420.915.7816
migraineSignal12420.917.72,337
suicidal ideationSignal8214.411.71,013
somnolenceSignal876.95.7441
insomniaSignal1096.65.5516
vomitingSignal1324.53.8365
headacheSignal1463.73.2300
depressionSignal453.22.466
anxietySignal563.22.482
product dose omission issueSignal512.82.157
nauseaSignal1302.62.2136
fatigueSignal1092.21.977
dizziness441.41.15
drug ineffective821.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.